REMODULIN\u00ae is the commercial brand name of Treprostinil Injection, developed by United Therapeutics Corporation. It is a stable prostacyclin analogue delivered via subcutaneous or intravenous infusion. It binds to prostacyclin receptors on vascular smooth muscle and platelets to dilate pulmonary and systemic blood vessels, inhibit platelet aggregation, reduce pulmonary vascular resistance and enhance cardiac output.<\/p>\n\n\n\n
Main Indications<\/strong> Clinical Research<\/strong> Common Side Effects<\/strong> Approval Status in China<\/strong> Buy REMODULIN (Treprostinil Injection)\u00a0online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.<\/p>\n","protected":false},"excerpt":{"rendered":" REMODULIN\u00ae is the commercial brand name of Treprostinil Injection, developed by United Therapeutics Corporation. It is a stable prostacyclin analogue delivered via subcutaneous or intravenous infusion. It binds to prostacyclin receptors on vascular smooth muscle and platelets to dilate pulmonary and systemic blood vessels, inhibit platelet aggregation, reduce pulmonary vascular resistance and enhance cardiac output. […]<\/p>\n","protected":false},"author":4,"featured_media":4445,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[101],"tags":[],"class_list":["post-4444","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-drug-news"],"blocksy_meta":[],"yoast_head":"\n
Treatment of pulmonary arterial hypertension (WHO Functional Class II-IV) to improve patients\u2019 exercise capacity and relieve related clinical symptoms.<\/p>\n\n\n\n
Global multicenter pivotal clinical trials fully validated its therapeutic value for pulmonary arterial hypertension. Core efficacy trials confirmed continuous infusion therapy effectively prolongs exercise tolerance and alleviates dyspnea under daily activities. Long-term observational trials demonstrated sustained hemodynamic improvement and delayed disease progression for patients with progressive pulmonary hypertension. Tolerability comparative studies reflected that most mild adverse symptoms appear during dose titration and can be relieved with gradual dose adjustment. Safety follow-up research proved manageable overall adverse event spectrum during long-term chronic infusion treatment.<\/p>\n\n\n\n
Common mild adverse reactions: Infusion site pain and erythema, facial flushing, headache, diarrhea, nausea, jaw pain and palpitations;
Laboratory abnormalities: Rare transient mild liver function fluctuation;
Severe but uncommon risks: Severe systemic hemorrhage, hypotension, pulmonary edema and hypersensitivity reactions.<\/p>\n\n\n\n
REMODULIN\u00ae (specification 20mL:20mg, 1 vial per box) obtained marketing approval in China in 2021. It is an injectable prescription orphan drug for pulmonary arterial hypertension treatment included in China\u2019s Category B medical insurance catalogue.<\/p>\n\n\n\n